Skip to main content

Health economic modeling for medical technologies in Europe

Early and comprehensive economic models to determine economic value proposition and inform healthcare decision-makers

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

New codes for in-vitro diagnostics added to the Belgian Nomenclature

On March 1, 2023, Belgian National Institute for Health and Disability Insurance (INAMI-RIZIV) updated three Articles of the Nomenclature related to in-vitro diagnostics.

Eight new codes with corresponding conditions of reimbursement were added to Article 24 “Clinical biology” (Biologie Clinique). Fees in this Article are typically reimbursed at a 25% level (with some exceptions, e.g., a 100% fee is paid to subcontractor laboratories). Some examples of newly introduced codes are presented below:

  • 545930 - 545941 “Placental growth factor (PlGF) and soluble fms-like tyrosine kinase-1 (sFlt-1) assay with the calculation of the ratio sFlt-1/PlGF”;
  • 552495 - 552506 “Use of viscoelastic tests in the diagnosis and follow-up of hemorrhages caused either by severe trauma, or in obstetrics and postpartum, or during liver disease, liver transplantation, or cardiac surgery”;
  • 552510 - 552521 “Quantitation of anti-PR3 or anti-MPO antibodies in patients with clinical signs of possible ANCA-associated vasculitis who do not have a diagnosis of ANCA-associated vasculitis”.

Three new codes with corresponding conditions of reimbursement were added to Article 24bis “Clinical biology” (Biologie Clinique), §1 “Molecular biology tests on the genetic material of microorganisms”. Fees in this Article are reimbursed at a 100% level. An example of a newly introduced code is 557115 - 557126 “Detection of at least three respiratory infection agents using a molecular amplification technique.”

Moreover, one new code with corresponding conditions of reimbursement was implemented in Article 33bis “Genetic tests” (Examens Genetiques).

See more details in French here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Contact us to get a free, three-month, no-obligation trial.